Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 5, 2004, Pages 1405-1409

  Wadsley, Jonathan C ^a   Bentzen, Søren M ^b,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b Gray Cancer Institute   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Head and neck cancer; Locoregional control; Overall survival

Indexed keywords

FRACTIONATION; REGRESSION ANALYSIS; TUMORS;

HYPOXIC SENSITIZERS; LOCOREGIONAL CONTROL (LRC); OVERALL SURVIVAL (OS);

RADIOTHERAPY;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; REVIEW;

EID: 10044252034     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.05.049     Document Type: Article

References (29)

1. Suit H.D., Westgate S.J. Impact of improved local control on survival. Int J Radiat Oncol Biol Phys. 12:1986;453-458
2. Strong E.W. Sites of treatment failure in head and neck cancer. Cancer Treat Symp. 2:1983;5-20
3. Bourhis J, Syz N, Overgaard J, et al. Conventional versus modified fractionated radiotherapy: Meta-analysis based on individual data of patients with head and neck squamous cell carcinoma (HNSCC) [Abstract]. Radiother Oncol 2002;64 (Suppl. 1):S25
4. Pignon J.P., Bourhis J., Domenge C. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma Three meta-analyses of updated individual data. Lancet. 355:2000;949-955
5. Stuschke M., Thames H.D. Hyperfractionated radiotherapy of human tumours Overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 37:1997;259-267
6. Mackenzie R.G., Hodson D.I., Browman G.P., et al. Hyperfractionated radiotherapy for locally advanced carcinoma of the head and neck. Curr Oncol. 8:2001;6-15
7. Mackenzie R.G., Hodson D.I., Browman G.P., et al. Accelerated radiotherapy for locally advanced carcinoma of the head and neck. Curr Oncol. 8:2001;16-27
8. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma Final analysis of a randomised trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 25:1992;231-241
9. Sanchiz F., Milla A., Torner J., et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 19:1990;1347-1350
10. Pinto L., Canary P., Araujo C., et al. Prospective randomised trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 21:1991;557-562
11. Cummings B, O'Sullivan B, Keane T. 5-year results of 4 week/twice daily radiation schedule - The Toronto trial [Abstract]. Radiother Oncol 2000;56(Suppl. 1):S8
12. Fu K., Pajak T., Trotti A. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 48:2000;7-16
13. Horiot J., Bontemps P., Van Den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers Results of the EORTC 22851 randomized trial. Radiother Oncol. 44:1997;111-121
14. Dische S., Saunders M., Barrett A., et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 44:1997;123-136
15. Van Den Bogaert W., Van Der Schueren E., Horiot J., et al. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer Long-term results and side effects. Radiother Oncol. 35:1995;91-99
16. Jackson S., Weir L., Hay J., et al. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 43:1997;39-46
17. Overgaard J., Sand Hansen H., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck DAHANCA 6 & 7 randomised controlled trial. Lancet. 362:2003;933-940
18. Hliniak A., Gwiazdowska B., Szutkowski Z., et al. A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: Influence of a 1 week shortening overall time. Radiother Oncol. 62:2002;1-10
19. Dobrowsky W., Naude J. Continuous hyperfrationated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol. 57:2000;119-124
20. Bourhis J, Lapeyre M, Rives M. Very accelerated radiotherapy in HNSCC: Results of the GORTEC 94-02 randomized trial [Abstract]. American Society for Clinical Oncology May 20-23, 2000, New Orleans, LA
21. Skladowski K., Maciejewski B., Golen M., et al. Randomized clinical trial on 7-day continuous accelerated irradiotion (CAIR) of head and neck cancer-Report on 3-year tumour control and normal tissue toxicity. Radiother Oncol. 55:2000;101-110
22. Poulsen M., Denham J., Peters L., et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck A Trans-Tasman Radiation Oncology Group study. Radiother Oncol. 60:2001;113-122
23. Olmi P., Crispino S., Fallai C., et al. Locoregionally advanced carcinoma of the oropharynx Conventional radiotherapy vs accelerated hyperfractionated radiotherapy vs concomitant radiotherapy and chemotherapy - A multicenter randomized trial. Int J Radiat Oncol Biol Phys. 55:2003;78-92
24. Eschwege F., Sancho-Garnier H., Chassagne D., et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys. 39:1997;275-281
25. Overgaard J., Sand Hansen H., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 46:1998;135-146
26. Lee D.-J., Cosmatos D., Marcial V., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 32:1995;567-576
27. Bentzen S.M. Towards evidence based radiation oncology Improving the design, analysis and reporting of clinical outcome studies in radiotherapy. Radiother Oncol. 46:1998;5-18
28. Bolla M., Barletink H., Garavaglia G., et al. EORTC guidelines for writing protocols for clinical trials of radiotherapy. Radiother Oncol. 36:1995;1-8
29. Nicolucci A., Girilli R., Alexanian A., et al. Quality, evolution and clinical implications of randomised controlled trials on treatment of lung cancer A lost opportunity for meta-analysis. JAMA. 262:1989;2101-2107